导读： 1—6月，我国新批准建立国家标准物质524项，同比增长78.8%，涉及研制单位51家。截至目前，市场监管总局累计批准建立国家标准物质18982项，标 准物质国际计量互认能力稳居国际第一梯队。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 从研制单位类型看， 企业申报标准物质379项，占比72.3%，同比增长86.7%；科研事业单位申报145项，占比27.7%，同比增长61.1%。 企业和科研事业单位新建标准物质总数均有大幅度增长，标准物质研制单位以企业为主，标准物质行业经济活力回暖加速。 从地域分布看， 华北地区新建标准物质234项，占比44.7%;华东地区新建标准物质124项，占比23.7%；东北地区新建标准物质62项，占比 11.8%;西北地区新建标准物质48项，占比9.2%；华南地区新建标准物质32项，占比6.1%;西南地区新建标准物质24项，占比4.5%；华中 地区未新建标准物质。华北地区新建标准物质数量最多，西南地区新建标准物质增速较低。 标准物质是开展化学、生物等检测活动必不可少的"标尺"和"砝码"。截至目前，市场监管 ...

【今年1 - 6月我国新批准524项国家标准物质，同比大增78.8%】今年1—6月，我国新批准建立524项国 家标准物质，同比增长78.8%，涉及51家研制单位。其中，国家一级标准物质31项，占比5.9%，同比增 47.6%；国家二级标准物质493项，占比94.1%，同比增81.3%。 从应用领域看，环境监测领域获批202 项，占比38.6%，同比增69.7%；制造业及石化产业领域150项，占比28.6%，同比增108.3%；食品与农 产品安全检测领域134项，占比25.6%，同比增78.6%；医疗卫生领域38项，占比7.2%，同比增40.7%。 各领域新建数量均明显增长，制造业增幅最大。 从研制单位类型看，企业申报379项，占比72.3%，同 比增86.7%；科研事业单位申报145项，占比27.7%，同比增61.1%。企业和科研事业单位新建总数大幅 增长，行业活力回暖加速。 从地域分布看，华北地区新建234项，占比44.7%；华东地区124项，占比 23.7%；东北地区62项，占比11.8%；西北地区48项，占比9.2%；华南地区32项，占比6.1%；西南地区 24项，占比4.5%；华中地区未新建。华北地区 ...

5月29日，博晖创新今日收盘5.93元，上涨2.07%，最新市净率3.52，总市值48.44亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.02亿元，同比-23.05%；净利润-4054437.18 元，同比-120.41%，销售毛利率38.37%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5博晖创新-330.17523.933.5248.44亿行业平均 49.6447.924.61106.85亿行业中值36.3637.152.4549.28亿1天益医疗-1776.29-3042.591.9022.64亿2澳华内 镜-644.66323.335.1667.94亿3诺唯赞-407.58-482.062.2487.22亿4爱朋医疗-359.62273.204.3329.51亿6奥精 医疗-139.08-203.851.8325.81亿7硕世生物-137.56-2010.081.2340.24亿8睿昂基因-102.37-84.041.4513.25亿9 康泰医学-89.13-75.303.1858.66亿10中红医疗-72.45-57.790.9250.35亿11华大智造-55.85- ...

Group 1 - The core business of Beijing Bohui Innovation Biotechnology Group Co., Ltd. is the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration products, quality control products, and national standard substances [1] - As of the first quarter of 2025, the company reported a revenue of 202 million yuan, a year-on-year decrease of 23.05%, and a net profit of -4.05 million yuan, a year-on-year decrease of 120.41%, with a gross profit margin of 38.37% [1] - The latest closing price of Bohui Innovation was 5.78 yuan, down 2.69%, with a price-to-book ratio of 3.43 and a total market value of 4.722 billion yuan [1] Group 2 - The company has one institutional holder with a total holding of 4.1405 million shares, valued at 2.3 million yuan [1] - The company's PE (TTM) is -321.82, while the industry average PE (TTM) is 48.71, indicating a significant underperformance compared to the industry [2] - The industry median price-to-book ratio is 2.40, while Bohui Innovation's price-to-book ratio is 3.43, suggesting a higher valuation relative to its peers [2]

Company Overview - Beijing Bohui Innovation Biotechnology Group Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration materials, quality control products, and national standard substances [1]. Financial Performance - For Q1 2025, the company reported revenue of 202 million yuan, a year-on-year decrease of 23.05% [1]. - The net profit for the same period was -4,054,437.18 yuan, reflecting a year-on-year decline of 120.41% [1]. - The gross profit margin stood at 38.37% [1]. Market Metrics - As of May 20, the company's stock closed at 5.94 yuan, up 1.54%, with a latest price-to-book ratio of 3.53, marking a 15-day low [1]. - The total market capitalization is 4.852 billion yuan [1]. - Over the past five days, the main capital flow showed a net inflow of 618,100 yuan, although the overall trend was a net outflow of 20.5314 million yuan [1]. Industry Comparison - The company's price-to-earnings (P/E) ratio (TTM) is -330.72, while the industry average is 49.51 [2]. - The company's price-to-earnings (static) ratio is 524.81, compared to the industry average of 47.73 [2]. - The industry median price-to-book ratio is 2.51, while Bohui Innovation's is 3.53 [2].